DWA
FBIO icon

Dorsey Wright & Associates’s Fortress Biotech FBIO Stock Holding History

Dorsey Wright & Associates’s Portfolio FBIO Stock Details FBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-142
Closed -$9K – 338
2020
Q3 		$9K Buy
+142
New +$7.23K ﹤0.01% 209

Other funds holding FBIO

Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SAM
Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return

Dorsey Wright & Associates's FBIO Position: Q4 2020 in Review

Dorsey Wright & Associates sold out of Fortress Biotech (FBIO) in Q4 2020, closing a stake of 142 shares — an estimated $9K sold.

Dorsey Wright & Associates first reported a position in FBIO in Q3 2020 and held it in 1 quarter. The position peaked at $9K in Q3 2020. 87 funds tracked by Wall St. Rank hold FBIO as of Q4 2020.

  • Dorsey Wright & Associates reported no remaining Fortress Biotech position as of Q4 2020 after selling out during the quarter.
  • Dorsey Wright & Associates sold 142 Fortress Biotech shares in Q4 2020, an estimated $9K.
  • Dorsey Wright & Associates first reported a position in Fortress Biotech in Q3 2020 and held it in 1 quarter.
  • Dorsey Wright & Associates's Fortress Biotech position peaked at $9K in Q3 2020.
  • 87 funds tracked by Wall St. Rank held Fortress Biotech as of Q4 2020.

Based on Dorsey Wright & Associates's 13F filing for Q4 2020, filed 28 Jan 2021.